Clinical Trial Update: Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial investigating EMA401 for postherpetic neuralgia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• EMA401

Snippet

Sponsor: Spinifex Pharmaceuticals Pty Ltd | Conditions: Neuralgia, Postherpetic | Phase 2 | Status: WITHDRAWN